caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
It belongs to the anti hypertensive class of molecules. | CC(=O)CC(=O)OCCOc1ccccc1CCOC1CCCCO1 | [
"anti hypertensive"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and aging. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts tangier disease, non-alcoholic fatty liver disease, and diabetic heart disease. | CC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Apoptosis",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Aging",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti hypertensive agent, a heart failure treatment, a cardiovascular treatment, and anti hypertensive. | CNc1cc(F)ccc1C(=O)OC(C)(C)C | [
"anti hypertensive agent",
"anti hypertensive",
"heart failure treatment",
"cardiovascular treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, fat storage, nutrient that impacts cardiovascular disease, pancreatitis, and metabolic syndrome. The molecule is a membrane stabilizer that impacts both obesity and cancer. The molecule is a inflammatory and a energy source, it impacts atherosclerosis, and is thyroxine treatment. | CC(C)CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Energy storage",
"Cardiovascular disease",
"Fat storage",
"nutrient",
"Pancreatitis",
"Metabolic syndrome",
"Obesity",
"Membrane stabilizer",
"Cancer",
"Atherosclerosis",
"Thyroxine treatment",
"inflammatory",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the organic electronic device class of molecules. | C1=Cc2ccc(-c3nc(-c4ccccc4)cc(-c4ccc(-c5cccnc5)cc4)n3)cc2C2(c3ccccc31)c1ccccc1-c1c2c2ccccc2c2ccccc12 | [
"organic electronic device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, tangier disease, and aging. The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation that impacts barth syndrome, aging, tangier disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Barth syndrome",
"Aging",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the cancer treatment class of molecules. | Cc1ccc(Nc2ccc(C(F)(F)F)cc2)c(-c2nnn(CCO)n2)c1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation that impacts tangier disease, barth syndrome, aging, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease. | CC(C)CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Tangier disease",
"Barth syndrome",
"Aging",
"Diabetic heart disease",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts alzheimer's disease, parkinson's disease, diabetes mellitus type 2, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCC=CO[C@H](COC(=O)CCC/C=C\C[C@H]1C=CC(=O)[C@@H]1/C=C/[C@@H](O)CCCCC)COP(=O)(O)OCCN | [
"Alzheimer's Disease",
"nutrient",
"Parkinson's disease",
"Diabetes mellitus type 2",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts aging, tangier disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase that impacts diabetic heart disease and non-alcoholic fatty liver disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Aging",
"Tangier disease",
"Barth syndrome",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts tangier disease and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Barth syndrome",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Apoptosis",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source and fat storage, affecting cancer, and impacting metabolic syndrome, atherosclerosis, and cardiovascular disease. The molecule is a inflammatory that impacts both obesity and pancreatitis. The molecule is a thyroxine treatment, energy storage, membrane stabilizer, nutrient. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Metabolic syndrome",
"Atherosclerosis",
"Cardiovascular disease",
"Energy source",
"Fat storage",
"Cancer",
"Obesity",
"Pancreatitis",
"inflammatory",
"Thyroxine treatment",
"Energy storage",
"Membrane stabilizer",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a immunomodulator and belongs to the cancer treatment class of molecules. | CC(=O)NCCNCc1ccc(OCc2cccc(-c3ccccc3)c2C)cc1OCc1ccccc1CO | [
"cancer treatment",
"immunomodulator"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts barth syndrome, diabetic heart disease, and aging. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts non-alcoholic fatty liver disease, diabetes mellitus type 2, parkinson's disease, and alzheimer's disease. | CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OCCN | [
"nutrient",
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2",
"Parkinson's disease",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a gsk3 inhibitor and belongs to both the diabetes treatment and alzheimer's treatment classes of molecules. | COc1cccc(OC)c1C(=O)c1sc(Nc2ccccc2)nc1N | [
"diabetes treatment",
"alzheimer's treatment",
"gsk3 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a surfactant, impacting both non-alcoholic fatty liver disease and tangier disease. The molecule is a energy source, proton trap for oxidative phosphorylation, membrane stabilizer, cholesterol translocation, energy storage. The molecule is a nutritional supplement and a food additive, it impacts aging, and is smooth. The molecule is a emulsifier, apoptosis, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"surfactant",
"Energy source",
"Proton trap for oxidative phosphorylation",
"Membrane stabilizer",
"Cholesterol translocation",
"Energy storage",
"Aging",
"Smooth",
"Nutritional supplement",
"food addit... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti bacterial, a cyclooxygenase2 inhibitor, a anti bacterial agent, and photochromic. | CC(Cl)Cl.CCCCCC.CCOC(C)=O | [
"anti bacterial",
"cyclooxygenase2 inhibitor",
"anti bacterial agent",
"photochromic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and barth syndrome. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts tangier disease, aging, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Barth syndrome",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, fat storage, and inflammatory that has an effect on cancer and impacts both atherosclerosis and pancreatitis. The molecule is a energy source that impacts both obesity and cardiovascular disease. The molecule is a nutrient and a membrane stabilizer, impacting both thyroxine treatment and metabolic syndrome. | CCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Energy storage",
"Cancer",
"Atherosclerosis",
"Pancreatitis",
"Fat storage",
"inflammatory",
"Obesity",
"Cardiovascular disease",
"Energy source",
"Thyroxine treatment",
"Metabolic syndrome",
"nutrient",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cysteine protease inhibitor, a protease inhibitor, and a cathepsin s inhibitor, and it impacts metabolic disease treatment. | Cn1c(=O)n(C2CCN(Cc3[nH]c(-c4ccc(C(F)(F)F)cc4)nc3-c3ccccc3)CC2)c2ccccc21 | [
"cysteine protease inhibitor",
"protease inhibitor",
"cathepsin s inhibitor",
"metabolic disease treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hcv inhibitor, a anti viral compound, a ns5a inhibitor, and anti viral. | CC(C)(C)OC(=O)N1C(c2nc3ccc(-c4ccc5c(c4)CCc4[nH]c(C6CC7CC7N6C(=O)OCc6ccccc6)nc4-5)cc3[nH]2)CC2CC21 | [
"anti viral",
"hcv inhibitor",
"anti viral compound",
"ns5a inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts barth syndrome. The molecule is a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Aging",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | COc1c(C(C)C)cc2c3c1OC(=O)C1CCC(C)(C)C(CC2)C31 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts tangier disease, diabetic heart disease, and barth syndrome. The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts aging and non-alcoholic fatty liver disease. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\CC(O)/C=C/C=C/C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a serine protease inhibitor and a factor xa inhibitor. | COC1CC(C(=O)Nc2ccc(-n3cccc(C#N)c3=O)cc2F)N(C(=O)Nc2ccc(Cl)cc2)C1 | [
"serine protease inhibitor",
"factor xa inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase that impacts barth syndrome and tangier disease. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts aging, diabetic heart disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts cervical cancer, atherosclerosis, ulcerative colitis, and breast cancer. | CCCCCCCC/C=C\CCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCC[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O | [
"Cervical cancer",
"nutrient",
"Atherosclerosis",
"Ulcerative colitis",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the thyroxine treatment class and affects both metabolic syndrome and atherosclerosis. The molecule is a fat storage and a nutrient, impacting both cardiovascular disease and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCC | [
"Thyroxine treatment",
"Metabolic syndrome",
"Atherosclerosis",
"Cardiovascular disease",
"Fat storage",
"nutrient",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts barth syndrome, diabetic heart disease, and aging. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts tangier disease and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Tangier disease",
"Apoptosis",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both metabolic syndrome and atherosclerosis. The molecule is a fat storage and a thyroxine treatment, impacting both cardiovascular disease and pancreatitis. | CCCCCC/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"Metabolic syndrome",
"nutrient",
"Atherosclerosis",
"Fat storage",
"Thyroxine treatment",
"Cardiovascular disease",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a organic optoelectronic device and belongs to the organic light-emitting diode class of molecules, with the characteristic of being optoelectronic. | CC1(C)c2ccccc2-c2ccc(-c3ccc4c(c3)c3cc(-c5ccc6c(c5)C(C)(C)c5c-6ccc6oc7ccccc7c56)ccc3n4-c3ccccc3)cc21 | [
"optoelectronic",
"organic optoelectronic device",
"organic light-emitting diode"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a renin inhibitor and a ace inhibitor, belonging to the hypertension treatment class of molecules. | CC(=O)c1cnc(C(O)C(CC2CCCCC2)NC(=O)C(Cc2cnc[nH]2)NC(=O)C(CC(=O)NCCCN2CCCC2=O)Cc2c[nH]c3ccccc23)[nH]1 | [
"renin inhibitor",
"ace inhibitor",
"hypertension treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts diabetes mellitus type 1, diabetes mellitus type 2, and pick's disease. The molecule is a nutrient that impacts atherosclerosis, insulin resistance, and cardiovascular disease. | CCCCCCCC/C=C\CC/C=C/[C@@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(=O)CCC/C=C\C/C=C\C/C=C\CC1OC1CCCCC | [
"Diabetes mellitus type 1",
"Diabetes mellitus type 2",
"Pick's disease",
"Atherosclerosis",
"Insulin resistance",
"Cardiovascular disease",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts barth syndrome, tangier disease, and aging. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Aging",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, parkinson's disease, non-alcoholic fatty liver disease, and alzheimer's disease. | CCCCC/C=C\C=C\C(=O)CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCc1oc(CCC)c(C)c1C)COP(=O)(O)OCCN | [
"Diabetes mellitus type 2",
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Alzheimer's Disease",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts diabetic heart disease and barth syndrome. The molecule is a cholesterol translocation and a apoptosis that impacts tangier disease, aging, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Cholesterol translocation",
"Apoptosis",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a faah inhibitor and a anxiety treatment. | O=C(CCCC1CCN(Cc2ccc3cccnc3n2)CC1)c1ncco1 | [
"faah inhibitor",
"anxiety treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, nutrient, inflammatory, and energy source, impacts obesity, and is thyroxine treatment. The molecule is a energy storage that affects cancer by impacting cardiovascular disease. The molecule is a membrane stabilizer that impacts metabolic syndrome, atherosclerosis, and pancreatitis. | CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCC(C)C | [
"Fat storage",
"nutrient",
"Thyroxine treatment",
"inflammatory",
"Energy source",
"Obesity",
"Energy storage",
"Cardiovascular disease",
"Cancer",
"Metabolic syndrome",
"Membrane stabilizer",
"Atherosclerosis",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a liquid crystal display device. | CCC(C)c1ccc(O)cc1 | [
"liquid crystal display device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a egfr inhibitor and a anti tumor. | CNCC=CC(=O)Nc1cc2c(Nc3ccc(OCCOCC(F)(F)F)c(Cl)c3)ncnc2cc1OCCOC | [
"egfr inhibitor",
"anti tumor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, inflammatory, fat storage that impacts cardiovascular disease, atherosclerosis, and obesity. The molecule is a member of the thyroxine treatment class and affects both pancreatitis and metabolic syndrome. The molecule is a energy storage, a energy source, and a membrane stabilizer, and it impacts cancer. | CC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | [
"Cardiovascular disease",
"Atherosclerosis",
"nutrient",
"inflammatory",
"Obesity",
"Fat storage",
"Thyroxine treatment",
"Pancreatitis",
"Metabolic syndrome",
"Energy storage",
"Cancer",
"Energy source",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts aging, tangier disease, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts non-alcoholic fatty liver disease and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti retroviral. | COc1ccc(CN2C(c3cccc([N+](=O)[O-])c3)C(C(=O)[O-])C(=O)C(C(=O)O)C2c2cccc([N+](=O)[O-])c2)cc1 | [
"anti retroviral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and aging. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts diabetic heart disease and barth syndrome. | CCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging",
"Diabetic heart disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts diabetic heart disease and tangier disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Cholesterol translocation",
"Apoptosis",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, inflammatory, energy source, energy storage, nutrient that impacts atherosclerosis. The molecule is a fat storage that impacts both obesity and metabolic syndrome. The molecule is a member of the thyroxine treatment class and affects cardiovascular disease, pancreatitis, and cancer. | CCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCC(C)C | [
"Membrane stabilizer",
"inflammatory",
"Energy source",
"Energy storage",
"Atherosclerosis",
"nutrient",
"Obesity",
"Metabolic syndrome",
"Fat storage",
"Cardiovascular disease",
"Thyroxine treatment",
"Pancreatitis",
"Cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is thyroxine treatment and it impacts both metabolic syndrome and cardiovascular disease. The molecule is a nutrient and a fat storage, impacting both pancreatitis and atherosclerosis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCC | [
"Metabolic syndrome",
"Cardiovascular disease",
"Thyroxine treatment",
"nutrient",
"Pancreatitis",
"Fat storage",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a hcv inhibitor and a anti viral. | C=CC1(C(F)(F)F)CC1 | [
"hcv inhibitor",
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a ec 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, cyclooxygenase inhibitor, pesticide and belongs to both the molluscicide and anti filarial classes of molecules. | C=CCCCCCCCC(=O)O | [
"molluscicide",
"EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor",
"cyclooxygenase inhibitor",
"pesticide",
"anti filarial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts breast cancer, diabetes mellitus, colorectal cancer, and cardiovascular disease. It impacts seizure, parkinson's disease, stomach cancer, and alzheimer's disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OC[C@@H]1COP(=O)(O)O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](C/C=C\CCCC(=O)O1)[C@@H](O)CC(O)O[C@H](/C=C\[C@@H](O)CCCCC)[C@@H](O)[C@H]2O | [
"Breast cancer",
"Diabetes mellitus",
"Colorectal cancer",
"Cardiovascular disease",
"Seizure",
"Parkinson's disease",
"Stomach cancer",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts diabetic heart disease and tangier disease. The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts barth syndrome, aging, and tangier disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome",
"Aging",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a organic electroluminescent device and belongs to the luminescent class of molecules, with the characteristic of being electroluminescent. | CC1(C)c2ccccc2-c2cc(N(c3ccc(-c4ccc(C5CCCCC5)cc4)cc3)c3ccc4ccccc4c3-c3ccc4c5ccccc5n(-c5ccccc5)c4c3)ccc21 | [
"luminescent",
"organic electroluminescent device",
"electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor. | CC1COC(NC(=O)c2cc(-n3ncc4cc(Nc5ccccc5Cl)cnc43)cs2)=N1 | [
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | COc1cc2c(c(C)c1C(=O)O)C(=O)c1c(O)cccc1C2=O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and tangier disease. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)CC | [
"Aging",
"Barth syndrome",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hcv polymerase inhibitor. | CCCc1ccc(CNC(=O)C2CN(c3ccc(C(=O)O)c(F)c3)CCN2S(=O)(=O)c2ccc(CC)cc2)cc1 | [
"hcv polymerase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protein kinase inhibitor, a kinase inhibitor, and a jnk inhibitor. | OCCN1CCN(CCCOc2cccc(Nc3nccc(-c4cnc(-c5cccc(OCc6ccccc6)c5)[nH]4)n3)c2)CC1 | [
"protein kinase inhibitor",
"kinase inhibitor",
"jnk inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomposition it emits toxic fumes of nitroxides. | CCCCNC | [
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a surfactant and a energy storage, impacting both barth syndrome and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, nutritional supplement, energy source, emulsifier, and smooth. The molecule is a membrane stabilizer, a apoptosis, and a food additive, and it impacts aging. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and tangier disease. | CCC(C)CCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"surfactant",
"Barth syndrome",
"Energy storage",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Nutritional supplement",
"Smooth",
"Energy source",
"Emulsifier",
"Membrane stabilizer",
"Aging",
"Apoptosis",
"food additive",
"Stabilizing mitochondrial structure",
"Non-alcoh... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts tangier disease. The molecule is a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, aging, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Cholesterol translocation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Diabetic heart disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts aging and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts diabetic heart disease, tangier disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Aging",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts aging and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Tangier disease",
"Apoptosis",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti viral, a anti cancer, and anti inflammatory. | CC(=O)N1CCN(S(=O)(=O)c2ccc(Oc3ccc(CN4CCC(N(C(=O)Nc5ccc(C)nc5)c5cccc(F)c5)CC4)cn3)cc2)CC1 | [
"anti viral",
"anti inflammatory",
"anti cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a protease inhibitor and belongs to the anti viral class of molecules. | CC1C(=O)N(c2nc3ccc([N+](=O)[O-])cc3s2)C2CCN(C(=O)C3CCCN3C(=O)OC(C)(C)C)C12 | [
"protease inhibitor",
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Aging",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a organic electroluminescent device and belongs to the electroluminescent class of molecules. | c1ccc(-c2cccc(-c3nc(-n4c5ccccc5c5c6c7ccccc7c7ccccc7c6c6ccccc6c54)nc4ccccc34)c2)cc1 | [
"electroluminescent",
"organic electroluminescent device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage, food additive, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure. The molecule is a stabilizing cytochrome oxidase, surfactant, membrane stabilizer, nutritional supplement that impacts tangier disease. The molecule is a cholesterol translocation and a energy source, impacting both aging and diabetic heart disease. The molecule is a emulsifier and a apoptosis, which impacts both non-alcoholic fatty liver disease and barth syndrome, and is characterized as smooth. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCC | [
"Energy storage",
"food additive",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"surfactant",
"Membrane stabilizer",
"Nutritional supplement",
"Tangier disease",
"Cholesterol translocation",
"Energy source",
"Aging",
"D... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts pancreatitis, atherosclerosis, and cardiovascular disease. The molecule is a fat storage and a nutrient, impacting both metabolic syndrome and thyroxine treatment. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Pancreatitis",
"Atherosclerosis",
"Cardiovascular disease",
"Metabolic syndrome",
"Thyroxine treatment",
"Fat storage",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a jak inhibitor. | CN(C)Cc1nsc(NC(=O)N2CC3CCCC3C2)n1 | [
"jak inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a protease inhibitor and a cathepsin inhibitor. | COc1ccc(C(=O)NC(CC(=O)O)c2ccccc2C)nc1-c1ccc(C#N)cc1 | [
"protease inhibitor",
"cathepsin inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and tangier disease. The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts diabetic heart disease and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | O=C(O)c1cc2c([nH]c3ccccc32)c(-c2ccco2)n1 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts pain treatment. | Cn1nnnc1-c1ccc2c(c1)Oc1ccccc1C2=C1CC2CCC(C1)N2 | [
"pain treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a vasoconstrictor agent, alpha-adrenergic agonist, non-narcotic analgesic, serotonergic agonist. | CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1 | [
"vasoconstrictor agent",
"alpha-adrenergic agonist",
"non-narcotic analgesic",
"serotonergic agonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti cancer class of molecules. | COc1ccc2nccc(Oc3ccc(CC(=O)O)c(OC)c3)c2n1 | [
"anti cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a angiotensin ii antagonist that impacts cardiovascular treatment. | COCCn1c(=O)[nH]c2nc(C3CCCCC3)n(Cc3ccc(-c4ccccc4-c4nn[nH]n4)cc3)c2c1=O | [
"cardiovascular treatment",
"angiotensin ii antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts diabetic heart disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts non-alcoholic fatty liver disease, barth syndrome, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Barth syndrome",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory and a membrane stabilizer that impacts cancer, metabolic syndrome, obesity, and cardiovascular disease. The molecule is a thyroxine treatment, a nutrient, and a energy source. The molecule is a energy storage and a fat storage, impacting both pancreatitis and atherosclerosis. | CCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Cancer",
"inflammatory",
"Metabolic syndrome",
"Obesity",
"Cardiovascular disease",
"Membrane stabilizer",
"Thyroxine treatment",
"nutrient",
"Energy source",
"Pancreatitis",
"Energy storage",
"Atherosclerosis",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts aging, barth syndrome, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Aging",
"Barth syndrome",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, membrane stabilizer, inflammatory that impacts obesity, atherosclerosis, and metabolic syndrome. The molecule is a fat storage that impacts both cardiovascular disease and thyroxine treatment. The molecule is a energy source and a energy storage, impacting both cancer and pancreatitis. | CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCC(C)C | [
"nutrient",
"Obesity",
"Atherosclerosis",
"Membrane stabilizer",
"Metabolic syndrome",
"inflammatory",
"Cardiovascular disease",
"Fat storage",
"Thyroxine treatment",
"Cancer",
"Pancreatitis",
"Energy source",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hiv replication inhibitor and hiv integrase inhibitor, and it impacts aids treatment. | CNC(=O)C1CN2CCN(Cc3ccc(Cl)c(Cl)c3)C(=O)C2=C1O | [
"hiv replication inhibitor",
"hiv integrase inhibitor",
"AIDs treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti bacterial. | CNC(C=O)C1Cc2cccc(Cl)c2C1 | [
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts diabetic heart disease. The molecule is a cholesterol translocation that impacts non-alcoholic fatty liver disease, tangier disease, barth syndrome, and aging. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Tangier disease",
"Barth syndrome",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease. The molecule is a cholesterol translocation that impacts barth syndrome, tangier disease, diabetic heart disease, and aging. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Tangier disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti viral class of molecules. | CC1=CCC(n2cc(C)c(=O)[nH]c2=O)O1 | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a asthma treatment and a pde4 inhibitor, belonging to the anti inflammatory class of molecules. | CC1(C)CCc2c(-c3ccoc3)nc3sc4c(NCCc5cnc[nH]5)ncnc4c3c2C1 | [
"anti inflammatory",
"asthma treatment",
"pde4 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy storage, nutrient, fat storage, inflammatory that impacts obesity. The molecule is a thyroxine treatment that impacts both atherosclerosis and pancreatitis. The molecule is a energy source that impacts cancer, cardiovascular disease, and metabolic syndrome. | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC | [
"Membrane stabilizer",
"Energy storage",
"nutrient",
"Fat storage",
"inflammatory",
"Obesity",
"Atherosclerosis",
"Thyroxine treatment",
"Pancreatitis",
"Cancer",
"Cardiovascular disease",
"Energy source",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a plasma kallikrein inhibitor. | Cc1nc(N2CC3C(C2)C3(F)F)ccc1Cc1ncc(Br)s1 | [
"plasma kallikrein inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a lrrk2 inhibitor and a cns disorder treatment. | Cc1cc2n[nH]nc2cc1C(=O)Nc1ccc2[nH]nc(-c3ccncc3)c2c1 | [
"lrrk2 inhibitor",
"cns disorder treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a mmp inhibitor and a matrix metalloproteinase inhibitor. | CCCCCCCOc1ccc(-c2ccc(C(=O)CC(CCCc3ccccc3)C(=O)O)cc2)cc1 | [
"mmp inhibitor",
"matrix metalloproteinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a aurora kinase inhibitor and is cancer treatment. | O=C(O)c1ccc(C#Cc2ncc3c(n2)-c2ccc(Cl)cc2C(c2cc(F)ccc2F)=NC3)cc1 | [
"aurora kinase inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on stomach cancer, and impacts parkinson's disease, colorectal cancer, and diabetes mellitus. It has an effect on breast cancer, and impacts alzheimer's disease, seizure, and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@@H]1COC(=O)C/C=C\C[C@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](OP(=O)(O)OC1)[C@H](OP(=O)(O)O)[C@H](O)[C@@H](/C=C/[C@H](O)CCCCC)[C@H](O)C[C@@H]2O | [
"Stomach cancer",
"Parkinson's disease",
"Colorectal cancer",
"Diabetes mellitus",
"Alzheimer's Disease",
"Breast cancer",
"Seizure",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting metabolic syndrome. The molecule is a fat storage that impacts cardiovascular disease, pancreatitis, and atherosclerosis. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC/C=C\CCCCCC)OCCCCCCCCCCCCCCCCCC | [
"nutrient",
"Metabolic syndrome",
"Thyroxine treatment",
"Cardiovascular disease",
"Pancreatitis",
"Fat storage",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti infective. | Cc1ccc(-c2sc(NC(=O)C3CCCC3)nc2C)cc1S(=O)(=O)Nc1ccc(Oc2ccc(C(F)(F)F)cc2)cc1 | [
"anti infective"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts barth syndrome, tangier disease, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts diabetic heart disease and aging. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a serine protease inhibitor and a type ii diabetes treatment. | N#CC1CCCN1C(=O)CNC1CC2(N3CCCS3(=O)=O)CCCC1C2 | [
"serine protease inhibitor",
"type ii diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.